NASDAQ:CARACara Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cara Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.04 +0.42 (+2.69 %) (As of 06/5/2020 12:47 PM ET) Add Compare Share Today's Range$15.62Now: $16.04▼$16.1550-Day Range$13.93MA: $15.29▼$16.4652-Week Range$8.88Now: $16.04▼$27.55Volume12,750 shsAverage Volume572,773 shsMarket Capitalization$750.67 millionP/E RatioN/ADividend YieldN/ABeta1.86 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that is in Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; and in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.40, Cara Therapeutics has a potential upside of 120.7% from its current price of $16.04.Amount of Analyst CoverageCara Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.2 Community Rank Outperform VotesCara Therapeutics has received 632 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCara Therapeutics has received 361 “underperform” votes. (Add your “underperform” vote.)Community SentimentCara Therapeutics has received 63.65% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote “Outperform” if you believe CARA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCara Therapeutics does not currently pay a dividend.Dividend GrowthCara Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $622,045.00 in company stock.Percentage Held by InsidersOnly 5.80% of the stock of Cara Therapeutics is held by insiders.Percentage Held by Institutions68.86% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cara Therapeutics are expected to decrease in the coming year, from ($2.59) to ($2.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cara Therapeutics is -6.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cara Therapeutics is -6.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCara Therapeutics has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.54 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CARA Previous Symbol CUSIPN/A CIK1346830 Webwww.caratherapeutics.com Phone203-406-3700Debt Debt-to-Equity Ratio0.02 Current Ratio4.07 Quick Ratio4.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$19.89 million Price / Sales37.74 Cash FlowN/A Price / Cash FlowN/A Book Value$4.66 per share Price / Book3.44Profitability EPS (Most Recent Fiscal Year)($2.49) Net Income$-106,370,000.00 Net Margins-480.29% Return on Equity-68.83% Return on Assets-53.81%Miscellaneous Employees55 Outstanding Shares46,800,000Market Cap$750.67 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:CARA Rates by TradingView Receive CARA News and Ratings via Email Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter. Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions How has Cara Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Cara Therapeutics' stock was trading at $13.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CARA shares have increased by 19.4% and is now trading at $16.04. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cara Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cara Therapeutics. When is Cara Therapeutics' next earnings date? Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Cara Therapeutics. How were Cara Therapeutics' earnings last quarter? Cara Therapeutics Inc (NASDAQ:CARA) posted its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.01. The biopharmaceutical company had revenue of $8.09 million for the quarter, compared to analyst estimates of $4.83 million. Cara Therapeutics had a negative return on equity of 68.83% and a negative net margin of 480.29%. View Cara Therapeutics' earnings history. What price target have analysts set for CARA? 5 brokerages have issued 12 month price targets for Cara Therapeutics' stock. Their forecasts range from $30.00 to $40.00. On average, they anticipate Cara Therapeutics' stock price to reach $35.40 in the next twelve months. This suggests a possible upside of 120.7% from the stock's current price. View analysts' price targets for Cara Therapeutics. Has Cara Therapeutics been receiving favorable news coverage? Media coverage about CARA stock has been trending somewhat positive on Friday, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cara Therapeutics earned a news impact score of 1.6 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutCara Therapeutics. Are investors shorting Cara Therapeutics? Cara Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 3,280,000 shares, a decline of 6.0% from the April 30th total of 3,490,000 shares. Based on an average daily volume of 514,400 shares, the days-to-cover ratio is currently 6.4 days. Currently, 7.7% of the shares of the stock are sold short. View Cara Therapeutics' Current Options Chain. Who are some of Cara Therapeutics' key competitors? Some companies that are related to Cara Therapeutics include Uniqure (QURE), Axsome Therapeutics (AXSM), Alkermes (ALKS), Insmed (INSM), Taro Pharmaceutical Industries (TARO), Amarin (AMRN), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT), Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), Ra Pharmaceuticals (RARX), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB) and Pacira Biosciences (PCRX). View all competitors. What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Canopy Growth (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), Insys Therapeutics (INSY), 22nd Century Group (XXII), Fate Therapeutics (FATE), GW Pharmaceuticals PLC- (GWPH), Novavax (NVAX) and BioMarin Pharmaceutical (BMRN). Who are Cara Therapeutics' key executives? Cara Therapeutics' management team includes the following people: Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 55)Dr. Frédérique Menzaghi, Chief Scientific Officer and Sr. VP of R&D (Age 53)Dr. Joana Goncalves, Chief Medical Officer (Age 45)Dr. Joseph Stauffer, Consultant (Age 53)Dr. Michael E. Lewis, Co-Founder & Chief Scientific Advisor (Age 67) What is Cara Therapeutics' stock symbol? Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA." Who are Cara Therapeutics' major shareholders? Cara Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.49%), Carmignac Gestion (3.82%), Chescapmanager LLC (2.79%), State Street Corp (2.19%), ETF Managers Group LLC (1.88%) and Disciplined Growth Investors Inc. MN (1.62%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View institutional ownership trends for Cara Therapeutics. Which major investors are selling Cara Therapeutics stock? CARA stock was sold by a variety of institutional investors in the last quarter, including Disciplined Growth Investors Inc. MN, BlackRock Inc., Pinnacle Associates Ltd., UBS Group AG, Two Sigma Investments LP, Squarepoint Ops LLC, Burrage Capital Management LLC, and JPMorgan Chase & Co.. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Mani Mohindru, and Scott Terrillion. View insider buying and selling activity for Cara Therapeutics. Which major investors are buying Cara Therapeutics stock? CARA stock was purchased by a variety of institutional investors in the last quarter, including Carmignac Gestion, Orbimed Advisors LLC, ETF Managers Group LLC, Geode Capital Management LLC, DAFNA Capital Management LLC, State Street Corp, Balyasny Asset Management LLC, and Parametric Portfolio Associates LLC. View insider buying and selling activity for Cara Therapeutics. How do I buy shares of Cara Therapeutics? Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cara Therapeutics' stock price today? One share of CARA stock can currently be purchased for approximately $16.04. How big of a company is Cara Therapeutics? Cara Therapeutics has a market capitalization of $750.67 million and generates $19.89 million in revenue each year. The biopharmaceutical company earns $-106,370,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe. What is Cara Therapeutics' official website? The official website for Cara Therapeutics is www.caratherapeutics.com. How can I contact Cara Therapeutics? Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700. This page was last updated on 6/5/2020 by MarketBeat.com Staff
